Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.30 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18259128 | 0.94 | TSHR (0.41) | TSHRALDH1A1TDP1THRBLMNA | |
| SCHEMBL1334934 | 0.85 | TSHR (0.44) | TSHRALDH1A1TDP1THRBLMNA | |
| SCHEMBL9453441 | 0.82 | TSHR (0.50) | TSHRALDH1A1THRBLMNASLC22A1 | |
| SCHEMBL8160689 | 0.82 | TSHR (0.50) | TSHRALDH1A1THRBLMNASLC22A1 | |
| SCHEMBL10894089 | 0.82 | TSHR (0.50) | TSHRALDH1A1THRBLMNASLC22A1 | |
| SCHEMBL131777 | 0.82 | TSHR (0.50) | TSHRALDH1A1THRBLMNASLC22A1 | |
| SCHEMBL17966475 | 0.82 | TSHR (0.50) | TSHRALDH1A1THRBLMNASLC22A1 | |
| SCHEMBL18108232 | 0.82 | TSHR (0.50) | TSHRALDH1A1THRBLMNASLC22A1 | |
| SCHEMBL21817839 | 0.82 | TSHR (0.50) | TSHRALDH1A1THRBLMNASLC22A1 | |
| SCHEMBL31286348 | 0.82 | TSHR (0.50) | TSHRALDH1A1THRBLMNASLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297343-B2 | Bioactive medical films | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1311551-A4 | BIOACTIVE COATING COMPOSITIONS AND METHODS | BIOSURFACE ENG TECH INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-6921811-B2 | Bioactive coating composition and methods | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040161442-A1 | Bioactive coating composition and methods | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040151764-A1 | Bioactive medical films | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2004-08-05 | — | — | US | disclosed |
| EP-1159302-B1 | NON-THROMBOGENIC SILYL MODIFIED HEPARIN COATING COMPOSITION AND METHODS FOR USING SAME | INNERDYNE MEDICAL INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6630580-B2 | Silyl heparin complex for use in attaching cells to prostheses, including vascular grafts and bone grafts | INNERDYNE, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6596699-B2 | Polyanion substrate having bound thereto by non-covalent means a condensate comprising a polycation and nucleic acid; for contacting surfaces of medical devices | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. | 2003-07-22 | — | — | US | disclosed |
| EP-1311551-A1 | BIOACTIVE COATING COMPOSITIONS AND METHODS | Biosurface Engineering Technologies, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020160098-A1 | Nucleic acid coating compositions and methods | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020115836-A1 | Non-thrombogenic coating composition and methods for using same | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002010221-A1 | BIOACTIVE COATING COMPOSITIONS AND METHODS | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| US-6342591-B1 | Amphipathic coating for modulating cellular adhesion composition and methods | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. | 2002-01-29 | — | — | US | disclosed |
| US-5955588-A | COVALENT COMPLEX OF 1 TO 30 HYDROPHOBIC SILYL MOIETIES DIRECTLY BOUND TO SODIUM HEPARIN VIA COVALENT BONDING; STABLE ANTICOAGULANT ACTIVITY OVER TIME; COST-EFFECTIVE PRODUCTION; FOR USE IN MEDICAL DEVICES | INNERDYNE, INC. (US) | 1999-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160098-A1 | Nucleic acid coating compositions and methods | HNRNPL, DNMT3L, HNRNPLL | TSHR 4108/4885ALDH1A1 4381/4885TDP1 1955/4885 |
| US-20040161442-A1 | Bioactive coating composition and methods | FGF2, FGF23, FGF1 | TSHR 992/4885ALDH1A1 1447/4885TDP1 4351/4885 |
| US-20020115836-A1 | Non-thrombogenic coating composition and methods for using same | SELL, ITGA1, F12 | TSHR 1981/4885ALDH1A1 1359/4885TDP1 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.